AR118859A1 - Composiciones y métodos de fabricación de células t - Google Patents
Composiciones y métodos de fabricación de células tInfo
- Publication number
- AR118859A1 AR118859A1 ARP200101269A ARP200101269A AR118859A1 AR 118859 A1 AR118859 A1 AR 118859A1 AR P200101269 A ARP200101269 A AR P200101269A AR P200101269 A ARP200101269 A AR P200101269A AR 118859 A1 AR118859 A1 AR 118859A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- manufacturing
- specific
- compositions
- methods
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 6
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000002659 cell therapy Methods 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/13—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Moulding By Coating Moulds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Casting Or Compression Moulding Of Plastics Or The Like (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845251P | 2019-05-08 | 2019-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118859A1 true AR118859A1 (es) | 2021-11-03 |
Family
ID=73051205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101269A AR118859A1 (es) | 2019-05-08 | 2020-05-05 | Composiciones y métodos de fabricación de células t |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220280621A1 (https=) |
| EP (1) | EP3965784A4 (https=) |
| JP (2) | JP7582971B2 (https=) |
| KR (2) | KR102756321B1 (https=) |
| CN (2) | CN121086984A (https=) |
| AR (1) | AR118859A1 (https=) |
| AU (1) | AU2020268397A1 (https=) |
| BR (1) | BR112021022363A2 (https=) |
| CA (1) | CA3137037A1 (https=) |
| IL (1) | IL287874A (https=) |
| MX (1) | MX2021013608A (https=) |
| PH (1) | PH12021552829A1 (https=) |
| SG (1) | SG11202112346WA (https=) |
| TW (2) | TWI777160B (https=) |
| WO (1) | WO2020227546A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| PT2812431T (pt) | 2012-02-09 | 2019-10-18 | Baylor College Medicine | Pepmixes para gerar ctls multivirais com larga especifidade |
| JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
| CA3081840A1 (en) | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
| KR20210040355A (ko) * | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
| TWI777160B (zh) * | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| EP4114400A4 (en) * | 2020-03-05 | 2023-10-18 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| US20230374455A1 (en) * | 2020-08-13 | 2023-11-23 | Biontech Us Inc. | T cell manufacturing compositions and methods |
| US11948694B2 (en) * | 2021-05-12 | 2024-04-02 | Merative Us L.P. | Controlling compartmental flows in epidemiological modeling based on mobility data |
| US12062456B2 (en) | 2021-05-27 | 2024-08-13 | Merative Us L.P. | Hypothetical scenario evaluation in infectious disease dynamics based on similar regions |
| IL312121A (en) * | 2021-10-15 | 2024-06-01 | Biontech Us Inc | T cell manufacturing compositions and methods |
| WO2023159088A1 (en) * | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
| IL321246A (en) * | 2022-12-09 | 2025-08-01 | Biontech Us Inc | Compositions and methods for producing T cells |
| WO2024151124A1 (ko) * | 2023-01-12 | 2024-07-18 | 주식회사 이뮤노맥스 | 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법 |
| CN117417886B (zh) * | 2023-10-20 | 2024-05-14 | 广东壹加再生医学研究院有限公司 | 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276478B2 (en) * | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| WO2006110582A1 (en) * | 2005-04-08 | 2006-10-19 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US9809797B2 (en) * | 2007-10-03 | 2017-11-07 | National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology | Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression |
| EP2749639B1 (en) * | 2012-02-10 | 2016-10-12 | Hakushinkouseikai Foundation | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
| RU2763795C2 (ru) * | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| DE102015214780A1 (de) * | 2015-08-03 | 2017-02-09 | Continental Automotive Gmbh | Verfahren zur Erkennung fehlerhafter Komponenten eines Kraftstoffeinspritzsystems |
| AU2016306408B2 (en) * | 2015-08-10 | 2021-02-11 | Toray Industries, Inc. | Immune inducer |
| EP3347051A4 (en) * | 2015-09-10 | 2019-04-24 | Affigen, Inc. | SEQUENCING SELECTING TUMOR THEROSTICAS |
| WO2017059557A1 (en) * | 2015-10-09 | 2017-04-13 | Peking University | Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use |
| AU2018337960B2 (en) * | 2017-09-20 | 2025-08-14 | Neximmune, Inc. | Cell compositions comprising antigen-specific T cells for adoptive therapy |
| CA3081840A1 (en) * | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
| TWI777160B (zh) * | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
-
2020
- 2020-05-05 TW TW109114957A patent/TWI777160B/zh active
- 2020-05-05 TW TW111130596A patent/TWI867324B/zh active
- 2020-05-05 AR ARP200101269A patent/AR118859A1/es unknown
- 2020-05-07 KR KR1020217040167A patent/KR102756321B1/ko active Active
- 2020-05-07 CA CA3137037A patent/CA3137037A1/en active Pending
- 2020-05-07 US US17/609,705 patent/US20220280621A1/en active Pending
- 2020-05-07 AU AU2020268397A patent/AU2020268397A1/en active Pending
- 2020-05-07 CN CN202511339181.5A patent/CN121086984A/zh active Pending
- 2020-05-07 JP JP2021566008A patent/JP7582971B2/ja active Active
- 2020-05-07 PH PH1/2021/552829A patent/PH12021552829A1/en unknown
- 2020-05-07 SG SG11202112346WA patent/SG11202112346WA/en unknown
- 2020-05-07 KR KR1020247036158A patent/KR20240161214A/ko active Pending
- 2020-05-07 CN CN202080050310.8A patent/CN114096261B/zh active Active
- 2020-05-07 BR BR112021022363A patent/BR112021022363A2/pt unknown
- 2020-05-07 WO PCT/US2020/031898 patent/WO2020227546A1/en not_active Ceased
- 2020-05-07 EP EP20801696.4A patent/EP3965784A4/en active Pending
- 2020-05-07 MX MX2021013608A patent/MX2021013608A/es unknown
-
2021
- 2021-11-07 IL IL287874A patent/IL287874A/en unknown
-
2024
- 2024-01-29 JP JP2024011014A patent/JP2024038503A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021013608A (es) | 2022-01-31 |
| KR20240161214A (ko) | 2024-11-12 |
| CN121086984A (zh) | 2025-12-09 |
| AU2020268397A1 (en) | 2022-01-06 |
| EP3965784A4 (en) | 2023-06-21 |
| PH12021552829A1 (en) | 2023-01-16 |
| SG11202112346WA (en) | 2021-12-30 |
| CN114096261B (zh) | 2025-09-26 |
| BR112021022363A2 (pt) | 2022-03-22 |
| EP3965784A1 (en) | 2022-03-16 |
| KR20220044242A (ko) | 2022-04-07 |
| KR102756321B1 (ko) | 2025-01-16 |
| CN114096261A (zh) | 2022-02-25 |
| WO2020227546A1 (en) | 2020-11-12 |
| TW202248419A (zh) | 2022-12-16 |
| US20220280621A1 (en) | 2022-09-08 |
| JP2024038503A (ja) | 2024-03-19 |
| JP2022531474A (ja) | 2022-07-06 |
| IL287874A (en) | 2022-01-01 |
| TWI777160B (zh) | 2022-09-11 |
| JP7582971B2 (ja) | 2024-11-13 |
| CA3137037A1 (en) | 2020-11-12 |
| TW202108761A (zh) | 2021-03-01 |
| TWI867324B (zh) | 2024-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118859A1 (es) | Composiciones y métodos de fabricación de células t | |
| WO2019094642A8 (en) | T cell manufacturing compositions and methods | |
| CO2023002953A2 (es) | Métodos y composiciones de fabricación de células t | |
| MX2020009441A (es) | Metodos para tratar las enfermedades asociadas al vph. | |
| PE20150223A1 (es) | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos | |
| MX2020004948A (es) | Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación. | |
| MX2020009773A (es) | Terapia de combinacion. | |
| MX2020003719A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| BR112019022901A2 (pt) | precursor de linhagem mesenquimal ou células t com imunossupressão intensificada | |
| ES2422605T3 (es) | Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| AR109707A1 (es) | Generación y uso en inmunoterapia adoptiva de células t de memoria tipo células madre | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| BR112015005653A2 (pt) | Método de promover o desenvolvimento de oócitos maduros e de aumentar a polimerização de actina em tecido ovariano, e uso de um agente que perturba a sinalização na trajetória hippo, ou um agente que age a jusante da sinalização hippo perturbada | |
| BR112021024946A2 (pt) | Célula de mamífero, método para produzir uma célula de mamífero implantável, e, uso de uma célula de mamífero | |
| BR112023013052A2 (pt) | Anticorpo monoclonal contra mac-1 humano e seus usos | |
| BR112018069090A2 (pt) | tratamento de câncer com base na distribuição de oligos por meio de junções comunicantes a partir de células estaminais mesenquimatosas humanas (hmsc) | |
| MX2021012335A (es) | Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2016000220A (es) | Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| BR112023020669A2 (pt) | Terapias de combinação para o tratamento de câncer | |
| MX2024003918A (es) | Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer. | |
| MX2021015403A (es) | Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario. |